[Efficacy and safety of denosumab in the treatment of prostate cancer with bone metastases: A systematic review and meta-analysis].
Denosumab can delay the time to first skeletal-related event with good safety. However, due to the limitations of this study, further high-quality, large-sample, multicenter RCTs are needed to confirm these findings.
Authors
- Xue-Jun Shang
- Xiaojun Qin
- Qiang Lou (ORCID: https://orcid.org/0000-0002-8253-0691)
- Yang Li (ORCID: https://orcid.org/0000-0002-3006-7420)
- Bo Fang (ORCID: https://orcid.org/0009-0003-3847-5765)
- Youping Xiao (ORCID: https://orcid.org/0009-0008-9700-0176)
- Xu-Xin Zhan
- Can-Qin He
Institutions
- Nanjing General Hospital of Nanjing Military Command (CN)
- The Fourth People's Hospital (CN)
- Affiliated Hospital of Guizhou Medical University (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- PubMed
- Published
- 2025-04-01
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00